

Biological Methods for Diagnosing Depressive Symptoms in Patients with Schizophrenia: A Narrative Review

Биологические методы диагностики депрессивных симптомов при шизофрении: нарративный обзор литературы

doi: 10.17816/CP15525

Review

Renata Sultanova¹, Vadim Gashkarimov²,
Ilya Efremov³, Azat Asadullin^{3,4,5}

¹ LLC Chayka Moscow City, Moscow, Russia

² Republican Clinical Psychiatric Hospital, Ufa, Russia

³ V.M. Bekhterev National Medical Research Center
for Psychiatry and Neurology, Saint Petersburg, Russia

⁴ Bashkir State Medical University, Ufa, Russia

⁵ Republican Clinical Center for Psychotherapy, Ufa, Russia

Рената Султанова¹, Вадим Гашкаримов²,
Илья Ефремов³, Азат Асадуллин^{3,4,5}

¹ ООО «Чайка Москва-Сити», Москва, Россия

² Республиканская клиническая психиатрическая
больница, Уфа, Россия

³ Национальный медицинский исследовательский
центр психиатрии и неврологии им. В.М. Бехтерева,
Санкт-Петербург, Россия

⁴ Башкирский государственный медицинский
университет, Уфа, Россия

⁵ Республиканский клинический психотерапевтический
центр, Уфа, Россия

ABSTRACT

BACKGROUND: Depressive symptoms in patients with schizophrenia lead to more frequent exacerbations of the underlying disease, worsen the prognosis, and increase the risk of suicide. Clinical practitioners continue to face challenges in diagnosing this disorder.

AIM: This study aims to analyze published material on biological markers of depressive symptoms in patients with schizophrenia.

METHODS: The search of literature was conducted using the following electronic search engines (the total number of relevant papers found is also specified): ACCESSSS ($n=150$), Cochrane Library ($n=48$), PubMed ($n=623$), eLIBRARY ($n=216$), and Google Scholar ($n=367$). The final discussion included 74 papers consistent with the study aim and were published between January 1, 2018 and December 31, 2023.

RESULTS: Based on the available scattered data, it appears that plasma biomarkers (e.g. C-reactive protein, metabolic parameters, hormones, enzymes, neurotrophic factors) are limited in specificity when it comes to diagnosing depressive symptoms in schizophrenia. Our analysis of the neuroimaging findings showed that depressive manifestations are associated with a decrease in the volume of the gray matter in the parietal, frontal, and temporal lobes (particularly in Broca's and Wernicke's areas) and in specific regions of the prefrontal cortex (including the medial right superior frontal, medial orbitofrontal, and superior and middle frontal gyri). It has been suggested that the *SIRT1*, *OXT*, *CDKAL1*, and *APOE* genes are involved in the development of depressive symptoms in patients with schizophrenia.

CONCLUSION: Understanding and identifying depressive symptoms in schizophrenia will improve the quality of care for patients with this disorder.

АННОТАЦИЯ

ВВЕДЕНИЕ: Депрессивная симптоматика при шизофрении приводит к более частым обострениям основного заболевания, ухудшению прогноза и повышению риска суицида. Перед клиницистами до сих пор стоит вопрос, связанный с трудностями диагностики этого расстройства.

ЦЕЛЬ: Произвести обзор литературы, направленный на поиск информации о биомаркерах депрессивных проявлений при шизофрении.

МЕТОДЫ: Поиск данных литературы осуществляли с применением следующих электронных сервисов для поиска публикаций (также указано общее число источников, обнаруженных по искомой теме): ACCESSSS ($n=150$), Cochrane Library ($n=48$), PubMed ($n=623$), eLIBRARY ($n=216$), Google Scholar ($n=367$). В итоговое обсуждение было включено 74 публикации, соответствующих цели работы и опубликованных не ранее 01.01.2018 и не позднее 31.12.2023.

РЕЗУЛЬТАТЫ: При суммировании разрозненных данных предположено, что плазменные показатели (концентрация С-реактивного белка, метаболические, гормональные, ферментативные показатели, значения нейротрофических факторов) слабоспецифичны для диагностики депрессивных симптомов при шизофрении. С помощью методов нейровизуализации установлено, что уменьшение объема серого вещества в теменной, лобной и височной доле (особенно в зонах Брока и Вернике), а также в префронтальной коре — в медиальной части правой верхней лобной, медиальной орбитофронтальной, верхней и средней фронтальных извилины — связано с депрессивными проявлениями. Предполагается связь между генами *SIRT1*, *OXT*, *CDKAL1* и *APOE* в возникновении депрессивных симптомов у пациентов с шизофренией.

ЗАКЛЮЧЕНИЕ: Понимание и выявление депрессивных симптомов при шизофрении позволит улучшить качество помощи, получаемой пациентами с этим расстройством.

Keywords: *depressive symptoms; schizophrenia; neurobiology*

Ключевые слова: *симптомы депрессии; шизофрения; нейробиология*

INTRODUCTION

Schizophrenia is a chronic mental disorder that affects approximately 1% of the global population [1]. In 1911, Bleuler identified affective disorders as one of the core symptoms in his "4A" framework (associations, affect, ambivalence, autism) for schizophrenia [2], a concept that continues to be recognized in modern diagnostic classifications. For instance, the International Classification of Diseases, 10th revision (ICD-10), includes both depressive and psychotic symptoms under the following categories [3]:

- F31.5 — Bipolar disorder, current episode depressed, severe, with psychotic features;
- F25.1 — Schizoaffective disorder, depressive type;
- F20.4 — Post-schizophrenic depression;

- F32.3 — Severe depressive episode with psychotic symptoms;
- F33.3 — Major depressive disorder, recurrent, severe without psychotic features.

When considering the overlap between affective and psychotic symptoms, most of the research focuses on schizoaffective disorder, which encompasses depressive episodes in the context of schizophrenia [4, 5]. However, depressive symptoms do not always meet the full diagnostic criteria for a depressive episode, which is why this review explores depressive manifestations of schizophrenia.

The transition from Liddle's two- (positive and negative symptoms) and three-factor model (positive symptoms, negative symptoms, and disorganization) of schizophrenia

[6] to the five-factor model underscores the distinct role and significance of depressive symptoms in the disease's structure. Reflecting on evolving diagnostic paradigms, Mosolov et al. [7] highlight the independence and value of the dimensional model in psychiatry. The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [1] outlines 8 clinical dimensions for schizophrenia spectrum and other psychotic disorders:

- hallucinations;
- delusional beliefs;
- disorganized speech;
- abnormal psychomotor behavior;
- negative symptoms;
- impaired cognition;
- depression;
- mania.

ICD-11 [8] identifies domains of schizophrenia and other primary psychotic disorders similar to dimensions (used as additional codes): positive, negative, depressive, manic, psychomotor, cognitive. Thus, the importance of identifying depressive symptoms is recognized in both classifications [9].

The relationship between schizophrenia and depressive symptoms is bidirectional: the presence of depressive symptoms worsens the course of schizophrenia, while a more severe progression of schizophrenia increases the likelihood of developing depressive symptoms [10]. The reported prevalence of depressive symptoms among individuals with schizophrenia varies widely, from 6% to 75% [11], depending on factors such as study design, disease stage, and diagnostic methods [12]. On average, depressive states occur in about 25% of patients with schizophrenia, a rate higher than that in the general population [13]. Additionally, depressive symptoms can manifest themselves at any stage of schizophrenia [14] and tend to be more severe in males [15]. These are often the most common and persistent symptoms of schizophrenia [16], contributing to reduced social functioning [10, 17], strained family relationships, and poorer treatment adherence [18]. Vauth et al. found that two-thirds of patients with schizophrenia are unable to fulfill basic social roles, and that only one-third are employed, often in positions requiring less qualifications than those they held before the onset of the illness [19]. As a result, depressive symptoms in schizophrenia contribute to dysfunction in the conduct of daily tasks [20]. Furthermore, the presence of depressive symptoms increases the risk of suicide in individuals with

schizophrenia [21] and suicide is a leading factor in the reduced life expectancy of these patients [22], particularly in the early stages of the disease [23].

While the diagnosis of schizophrenia remained based on the presence of specific symptoms according to ICD-10 criteria [3], it also is a highly heterogeneous disorder. Although biomarkers are widely used in other areas of medicine, they remain absent for psychiatric conditions like schizophrenia [24]. Understanding the pathophysiology of depressive symptoms in schizophrenia could improve diagnosis and inform more effective treatment choices [25].

The aim of this review is to analyze publications focused on identifying biological markers of depressive symptoms in schizophrenia.

METHODS

Eligibility criteria

Inclusion criteria:

- study participants had a confirmed diagnosis of "Schizophrenia" with depressive manifestations;
- studies aimed at identifying biological markers of depressive symptoms in schizophrenia;
- publication in English and/or in Russian;
- the period of publication is from January 01, 2018, to December 31, 2023.

Exclusion criteria:

- study participants had disorders comorbid with schizophrenia, including a depressive and/or manic episode.

Information sources

The search for papers was conducted using the following keywords in both Russian and English (as well as their combinations): "depressive symptoms", "schizophrenia", "neurobiology", "biological markers", "blood plasma", "gene". Articles from January 01, 2018, to December 31, 2023, were selected. This time period was selected to encompass the most relevant studies based on their recency. The group of authors conducted the information search process in turn and collegially. Each of the authors took equal part in the development of inclusion and exclusion criteria, data selection, information processing, and the writing of the literature review.

Search strategy

The search was conducted according to the principles of the clinical decision-making model "6S Hierarchy of




Figure 1. PRISMA flow diagram of the literature search and the selection process.

Source: Sultanova et al., 2024.

EBM Resources”¹ [26] using the service for the search for publications ACCESSSS from McMaster PLUS² (Figure 1).

The structure of the “6S Hierarchy of EBM Resources” model is presented in Figure 2.

The search resulted in the extraction of clinical guidelines from DynaMed ($n=40$), BMJ Best Practice ($n=30$), and EBM Guidelines ($n=9$), from which all papers were excluded by abstract and title ($n=79$), as none of them met the selection criteria. No systematic guidelines were identified, and the next stage of the search included systematic review-level studies (ACP Journal Club, $n=2$; McMaster PLUS, $n=18$). None of the studies met the inclusion criteria ($n=20$). Further screening was performed from unrated sources ($n=51$),

including UpToDate, of which 5 articles met the criteria and were included in the current review.

Two publications from the Cochrane Library ($n=48$) were included in the review³. Studies ($n=839$) were also extracted from the PubMed ($n=623$)⁴ and eLIBRARY ($n=216$)⁵ portals, of which 26 were included in the final version of the article (duplicates were excluded beforehand). The remaining sources were selected in Google Scholar ($n=367$), and 41 sources were included in the final version of the paper. The primary challenge in the search was ensuring the careful exclusion of studies where patients with schizophrenia had a comorbid depressive disorder, as this review focuses solely on publications addressing depressive manifestations at the symptomatic level.

¹ 6S Hierarchy of EBM Resources is a hierarchy of resources (information sources) based on evidence-based medicine and provides a model for guiding clinical decision-making.

² Available from: <https://www.accessss.org/>

³ Cochrane [Internet]. London: Cochrane [cited 2024 Aug 26]. Available from: <https://www.cochrane.org>

⁴ PubMed [Internet]. Bethesda: National Center for Biotechnology Information, U.S. National Library of Medicine [cited 2024 Aug 26]. Available from: <https://pubmed.ncbi.nlm.nih.gov>

⁵ eLIBRARY.RU [Internet]. Moscow: Scientific Electronic Library [cited 2024 Aug 26]. Available from: <https://elibrary.ru>




Figure 2. The 6S Hierarchy of EBM Resources model using McMaster PLUS’s ACCESSSS.

Note: DynaMed⁶ is a medical information Internet resource; Best Practice⁷ is an information Internet resource that physicians can use to make clinical decisions; EBM Guidelines⁸ are clinical guidelines based on the principles of evidence-based medicine; ACP Journal Club⁹ is a medical publication that publishes current literature on internal medicine; McMaster PLUS¹⁰ is a service of the research unit of the medical information of McMaster University (Canada); UpToDate¹¹ is a medical Internet resource providing medical information based on evidence-based information. *Source:* Sultanova et al., 2024.

Analysis of the results

Two reviewers independently reviewed all the verified documents. As a result, 74 papers were included in the current review. The publications found and selected for analysis were studied in full (full-text versions of

the manuscripts). The data were analyzed from the perspective of utilizing biological methods to study depressive manifestations in schizophrenia. As a result, it was decided to divide the presented results into three blocks:

⁶ DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 [cited 2024 Aug 26]. Available from: <https://www.dynamed.com>

⁷ BMJ Best Practice — a resource that physicians can use to make clinical decisions [Internet]. London: BMJ Publishing Group Limited [cited 2024 Aug 26]. Available from: <https://bestpractice.bmj.com/info>

⁸ EBM — Evidence-Based Medicine Guidelines [Internet]. Helsinki: Duodecim Medical Publications Ltd [cited 2024 Aug 26]. Available from: <https://www.ebm-guidelines.com/apps/dtk/ebmg>

⁹ ACP Journal Club — a medical publication that publishes current literature on internal medicine [Internet]. Philadelphia: American College of Physicians [cited 2024 Aug 26]. Available from: <https://www.acponline.org/clinical-information/journals-publications/acp-journal-club>

¹⁰ McMaster PLUS — a service of the research unit of the medical information of McMaster University (Canada) [Internet]. Hamilton: McMaster University [cited 2024 Aug 26]. Available from: <https://plus.mcmaster.ca/McMasterPLUSDB>

¹¹ UpToDate provide medical information based on evidence-based information [Internet]. Waltham: UpToDate, Inc. [cited 2024 Aug 26]. Available from: <https://www.uptodate.com/login>

- biochemical factors of depressive symptoms in schizophrenia;
- neuroimaging methods of depressive symptoms in schizophrenia; and
- genetic predictors in patients with schizophrenia with depressive manifestations.

Statistical methods were not used for data analysis.

RESULTS

Biochemical factors of depressive symptoms in schizophrenia

The data collection process began with an examination of biochemical markers in blood plasma, as it is a widely accessible and commonly used research method. Faugere et al. found that elevated C-reactive protein levels were associated with the presence of depressive symptoms in patients with schizophrenia [27]. Another study revealed a link between depressive symptoms in schizophrenia and elevated metabolic parameters, particularly triglycerides and low-density lipoproteins [28]. It has been found that, the peptide hormone leptin may influence the appearance of depressive symptoms in schizophrenia, with significantly higher levels observed in patients with depressive manifestations compared to healthy individuals. Moreover, leptin levels were shown to negatively correlate with the depression factor on the PANSS (Positive and Negative Syndrome Scale), though not on other subscales [29]. Other researchers identified a correlation between a higher dietary intake of glutamic acid and increased depressive symptoms in non-obese adults with schizophrenia, while no such correlation was observed in obese participants [30]. Further study demonstrated a connection between adiponectin, a hormone involved in fatty acid breakdown and glucose regulation, and depressive symptoms in schizophrenia, with lower baseline adiponectin levels being significantly associated with higher baseline depressive symptoms [31].

Research on biomarkers related to the body's defense mechanisms revealed a correlation between depressive symptoms and the antioxidant enzymes manganese superoxide dismutase and total superoxide dismutase activity in the blood plasma of patients experiencing their first episode of untreated schizophrenia [32]. In a study by Bigseth et al., elevated levels of the soluble urokinase plasminogen activator receptor (suPAR) were linked to depressive symptoms in women with schizophrenia, suggesting abnormal immune activation within this subgroup [33].

Brain-derived neurotrophic factor (*BDNF*), a key modulator of neuroplasticity, is implicated in the pathogenesis of both schizophrenia and depression [34]. Although *BDNF* is not a specific synaptic molecule, research has shown that reduced serum *BDNF* levels in patients with schizophrenia are associated with more severe depressive symptoms [35], particularly in the early stages of the illness [36]. Han et al. study of patients with schizophrenia and depressive symptoms who were on monotherapy with olanzapine for 12 weeks demonstrated a significant increase in *BDNF* levels and a reduction in depressive symptoms following treatment [37]. Additionally, it was found that the concentration of another neurotrophic factor, neurotrophin-3 (NT-3), increased in the serum of patients with schizophrenia only in the presence of depressive symptoms, with no significant difference in NT-3 levels between schizophrenic patients and a control group in the absence of depression [38].

Neuroimaging methods of depressive manifestations in schizophrenia

Neuroimaging is a key research tool in schizophrenia studies. In a meta-analysis of 4474 patients with schizophrenia and 5098 controls, brain imaging of cortical thickness and surface area abnormalities revealed a decreased gray matter volume in regions crucial to both schizophrenia [39] and depression [40]. Specifically, a reduced gray matter volume in the prefrontal cortex, including the medial part of the right superior frontal, medial orbitofrontal, and superior and middle frontal gyri, was linked to depressive symptoms in schizophrenia patients. Notably, depressive symptoms in schizophrenia had a more significant impact on gray matter reduction than negative symptoms [41]. According to magnetic resonance morphometry, a comparison between schizophrenia patients with/without depressive symptoms with a healthy control group indicated pronounced gray matter abnormalities concentrated in the cingulate gyrus in schizophrenia patients with depressive symptoms [42]. The reduction in gray matter was most significant in first-episode schizophrenia patients with depressive symptoms, especially in the parietal, frontal, and temporal lobes, including Broca's and Wernicke's areas, and the prefrontal cortex [43]. In comparisons of patients with depressive episodes and psychotic symptoms and those with schizophrenia and depressive symptoms, the latter group showed reduced gray matter in the left tegmental area and left frontal lobe [44].

Although electroencephalography (EEG) is not a neuroimaging method, a study by Shor et al. using EEG demonstrated that patients with both schizophrenia and depression exhibit lower hierarchical interconnectivity and reduced information segregation compared to healthy controls [45].

In animal studies, *in vivo* two-photon calcium imaging and electrophysiological recordings, combined with behavioral phenotyping, were used to investigate schizophrenia models. To create a mouse model of schizophrenia, the animals received dizocilpine (an N-methyl-D-aspartate, NMDA antagonist); depressogenic factors were created three days after the injection by tilting the cage, wet bedding, forced swimming, physical restraint, and sleep deprivation. The study found that schizophrenia with depression is expressed by a variety of symptoms, including helplessness, anhedonia and reduced filtering of sensory information, having worse indicators for these symptoms than depression or schizophrenia alone. These behavioral deficits were associated with disrupted neuronal calcium activity in the frontal cortex and thalamic nuclei [46, 47].

Genetic predictors in schizophrenia patients with depressive symptoms

Research on candidate genes has identified a number of common genetic factors associated with depressive manifestations in schizophrenia. One such gene is the methylenetetrahydrofolate reductase (*MTHFR*) gene [48]. In our study, while we did not uncover an association with the *MTHFR* C677 polymorphism, we found that elevated homocysteine levels may serve as a risk factor for the development of depressive symptoms in patients with schizophrenia [49].

Low levels of *BDNF* and *SIRT1* have also been implicated in the emergence of depressive symptoms in schizophrenia [50]. However, the *BDNF* gene contains multiple single nucleotide polymorphisms (SNPs) that exhibit strong linkage disequilibrium and interact in ways that may affect susceptibility to a mental illness. This complexity suggests the need for further detailed investigations of the gene [51]. The *SIRT1* gene encodes a protein belonging to the sirtuin family, whose functions are not yet fully understood. However, emerging evidence suggests that this gene may play a role in the pathogenesis of depression [52]. Preliminary findings from one study indicate that the *SIRT1* gene may increase the susceptibility of patients with schizophrenia to depressive symptoms [53].

Oxytocin, a regulator of social and emotional behavior, is a promising candidate for assessing susceptibility to schizophrenia. Research on schizophrenia patients suggests that oxytocin may play a role in the cognitive and social deficits development, possibly due to overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, a known contributor to neurodegenerative changes in schizophrenia. Given its involvement in emotion and facial expression recognition, oxytocin has become a focal point for studying the pathophysiology of negative and depressive symptoms in schizophrenia, particularly reduced emotional expression. A study by Broniarczyk-Czarniak et al. demonstrated a correlation between the expression of the *OXT* gene, at both the mRNA and protein levels, and the severity of depressive symptoms in schizophrenia patients [54].

The impact of lipid metabolism disorders in schizophrenia patients has attracted particular attention from researchers. They have proposed a genetic link between depressive symptoms and lipid metabolism. Preliminary evidence indicates that the rs7754840 polymorphism of the *CDKAL1* gene, which is crucial for lipid metabolism, may contribute to the development of depressive symptoms in drug-naive schizophrenia patients [55]. Additionally, a study by Li revealed that the apolipoprotein E gene (*APOE E2*) is associated with the emergence of depressive symptoms in schizophrenia patients [56].

DISCUSSION

Brief interpretation of results

In this literature review, we consolidate the disparate data on biological markers of depressive symptoms in schizophrenia. Upon reviewing blood parameters, it becomes evident that this method cannot currently be considered specific for diagnosing depressive manifestations in schizophrenia. Changes in the concentration of proteins, such as C-reactive protein, soluble urokinase plasminogen activator receptor (suPAR), enzymes (superoxide dismutase), metabolic markers (triglycerides and low-density lipoproteins), and hormonal profile markers (leptin and adiponectin), are also observed in other conditions.

Analyzing the literature data on blood parameters, we obtained information on the influence of neurotrophic factors. For instance, NT-3 levels were significantly elevated, while *BDNF* levels were decreased in patients with schizophrenia experiencing depressive symptoms. However, these findings cannot be currently used as a diagnostic feature as they lack specificity, as reduced

BDNF levels are also associated with several other psychiatric disorders. Based on current evidence, it can be concluded that blood parameters cannot yet be used as specific markers for identifying depressive symptoms in schizophrenia, prompting an attempt to explore other research methods.

Clarifying the neural mechanisms by which depressive symptoms exacerbate the course of schizophrenia is essential for identifying new therapeutic targets and developing treatment strategies [57]. In a study of depression and psychosis, Lalouis et al. [58] suggested that a neurobiologically driven approach is more effective in predicting symptomatic and functional remission than traditional diagnostic categories in predicting the course of the disease. A reduction in the gray matter volume [41] has been observed in the parietal, frontal, and temporal lobes, particularly in Broca's and Wernicke's areas [43], as well as in the prefrontal cortex, including the medial part of the right superior frontal, medial orbitofrontal, and superior and middle frontal gyri [42, 44]. Several studies have confirmed gray matter reduction in cases of depressive symptoms in schizophrenia, though some findings require further confirmation through additional research [45–47].

The results of the analysis of candidate genes that contribute to the development of depressive symptoms in schizophrenia were also presented. The *SIRT1* [50, 53], *OXT* [54], *CDKAL1* [55], and *APOE* [56] genes may contribute to the development of depressive symptoms in a sample of patients with schizophrenia. However, findings on the *MTHFR* gene remain inconsistent and require further investigation [48, 49]. Although genetic studies have limitations, the search for genetic associations represents one of the most promising approaches for identifying biological markers, particularly in patients with depressive symptoms in schizophrenia. An equally important issue for clinicians is the differential diagnosis of depressive symptoms in schizophrenia, which can be complicated by adverse reactions to antipsychotic medication [59, 60], substance abuse [61], and psychosis-related manifestations that may induce depression [62, 63]. A key challenge in diagnosis is distinguishing between depressive and negative symptoms [64]. Some researchers posit that negative symptoms are not exclusive to schizophrenia but may also occur in depressive disorders [65]. Negative symptoms can be secondary to depression or overlap with depressive features [66]. Other researchers emphasize

certain shared characteristics, such as anergia, poverty of speech, and anhedonia, while recommending a symptom-based approach for differentiation: depression is associated with hopelessness, pessimistic and suicidal thoughts, while negative symptoms are characterized by blunted affect, poverty of speech, objective depression, social withdrawal, and reduced attention span [57]. Nevertheless, network analysis has shown that depressive symptoms in schizophrenia are weakly correlated with negative symptoms, making them relatively distinguishable [67]. The complexities inherent in differentiating depressive manifestations in schizophrenia result in many patients receiving inadequate treatment, underscoring the need for further research into biological markers [29].

Limitations

One limitation of this review is the six-year publication window for the analyzed studies. The studies included were notably heterogeneous, with varying methods used to diagnose depressive symptoms in schizophrenia. The sample comprised both treatment-experienced and naive patients, which adds to variability. While the data on biological markers show promise for research, these markers must undergo standardization, sensitivity and specificity testing, and validation before they can be introduced into clinical practice. The practical relevance of these findings lies in the potential for neurobiological methods to improve the diagnosis of depressive symptoms in schizophrenia, enhancing research practices and facilitating psychiatrists' clinical work. This is particularly relevant given the challenges in differentiating depressive symptoms from negative symptoms, which remain significant. Early detection of depressive symptoms is also crucial for preventing severe complications, such as completed suicide attempts. Overall, the review underscores the considerable potential of neurobiology in diagnosing depressive manifestations in schizophrenia. The adoption of these methods could lead to significant improvements in diagnosis, treatment, and, ultimately, the quality of life for these patients.

CONCLUSION

In recent years, numerous studies have explored the neurobiological aspects of depressive symptoms in schizophrenia. However, it remains premature to implement these diagnostic methods in routine clinical practice. Continued research into biological markers will provide

greater clarity about the development of depressive symptoms in schizophrenia and will influence the choice of priority treatment methods.

Article history

Submitted: 26.03.2024

Accepted: 22.09.2024

Published Online: 26.09.2024

Authors' contribution: All the authors made a significant contribution to the article.

Funding: The research was carried out without additional funding.

Conflict of interest: The authors declare no conflicts of interest.

For citation:

Sultanova RI, Gashkarimov VR, Efremov IS, Asadullin AR. Biological methods for diagnosing depressive symptoms in patients with schizophrenia: a narrative review. *Consortium Psychiatricum*. 2024;5(3): CP15525. doi: 10.17816/CP15525

Information about the authors

***Renata Ildarovna Sultanova**, MD, psychiatrist, LLC Chayka Moscow City; ORCID: <https://orcid.org/0000-0001-6679-4454>, e-Library SPIN-code: 8284-845 E-mail: renatasu@mail.ru

Vadim Rimovich Gashkarimov, MD, clinical resident-psychiatrist, Republican Clinical Psychiatric Hospital; ORCID: <https://orcid.org/0000-0001-9944-141X>, e-Library SPIN-code: 3828-4634

Ilya Segeevich Efremov, MD, Cand. Sci. (Med.), Assistant, Department of Psychiatry, Narcology and Psychotherapy Bashkir State Medical University; Junior Researcher, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; ORCID: <https://orcid.org/0000-0002-9994-8656>, e-Library SPIN-code: 9983-8464

Azat Railevich Asadullin, MD, Dr. Sci. (Med.), Professor, Department of Psychiatry, Narcology and Psychotherapy Bashkir State Medical University; Leading Researcher, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Deputy Medical Director, Republican Clinical Psychotherapeutic Center; ORCID: <https://orcid.org/0000-0001-7148-4485>, e-Library SPIN-code: 3740-7843

*corresponding author

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Publishing; 2013. 947 p. doi: 10.1176/appi.books.9780890425596
2. Bleuler E. Dementia praecox, oder Gruppe der Schizophrenien. Leipzig und Vienna: F. Deuticke; 1911. 420 S.

3. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research ICD-10. Geneva: World Health Organization; 1993. 248 p.
4. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? *Schizophr Bull*. 2017;43(2):240–244. doi: 10.1093/schbul/sbw097
5. Mosolov SN. Diagnosis and treatment depression in schizophrenia. *Consort Psychiatr*. 2020;1(2):29–42. doi: 10.17816/CP29-42
6. Bassett AS, Bury A, Honer WG. Testing Liddle's three-syndrome model in families with schizophrenia. *Schizophr Res*. 1994;12(3):213–221. doi: 10.1016/0920-9964(94)90031-0
7. Mosolov SN, Malyutin AV, Pikalov AA. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine]. *Zhurnal neurologii i psikiatrii imeni S. S. Korsakova*. 2019;119(12):29–37. Russian. doi: 10.17116/jnevro201911912129
8. ICD-11 for mortality and morbidity statistics [Internet]. 2018 [cited 2022 Jul 25]. Available from: <https://icd.who.int/browse/2018/mms/en>
9. Pavlichenko AV, Kulygina MA, Kostyuk GP. [Schizophrenia and other psychotic disorders in ICD-11 and DSM-5: evolution of the concepts and current status]. *Zhurnal neurologii i psikiatrii imeni S. S. Korsakova*. 2020;120(6 Iss. 2):5–12. Russian.
10. Liu J, Chan TCT, Chong SA, et al. Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. *Early Interv Psychiatry*. 2020;14(6):691–697. doi: 10.1111/eip.12895
11. Kim M, Lee Y, Kang H. Effects of Exercise on Positive Symptoms, Negative Symptoms, and Depression in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2023;20(4):3719. doi: 10.3390/ijerph20043719
12. Novitskiy MA, Shnayder NA, Bugay VA, et al. [Use of parametric methods and questionnaires for the study of depressive and anxiety disorders in schizophrenia]. *Doctor.Ru*. 2021;20(5):55–61. Russian. doi: 10.31550/1727-2378-2021-20-5-55-61
13. Siris SG, Braga RJ. Depression in schizophrenia [Internet]. 2023 [cited 2024 Jul 12]. Available from: <https://medilibr.ir/uptodate/show/14791>
14. Mazom GE, Ganzenko MA, Rukavishnikov GV, et al. [Depression in schizophrenia: approaches to therapy: methodological recommendations]. Saint Petersburg: V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology; 2020. 22 p. Russian.
15. Andira S, Nuralita NS. [Influence of Sexual Differences on Depressive Symptom of Schizophrenia Patients in Rumah Sakit Jiwa Prof. Dr. M. Ildrem Medan North Sumatra 2017]. *Buletin Farmatera*. 2018;3(2):97–108. Indonesian.
16. Häfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. *Psychiatry J*. 2019;9804836. doi: 10.1155/2019/9804836
17. Wang TT, Beckstead JW, Yang CY. Social interaction skills and depressive symptoms in people diagnosed with

- schizophrenia: The mediating role of auditory hallucinations. *Int J Ment Health Nurs*. 2019;28(6):1318–1327. doi: 10.1111/inm.12643
18. McGinty J, Haque MS, Upthegrove R. Depression during first episode psychosis and subsequent suicide risk: a systematic review and meta-analysis. *Schizophr Res*. 2018;195:58–66. doi: 10.1016/j.schres.2017.09.040
 19. Vauth R, Carpiniello B, Turczyński J, et al. Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. *Int J Methods Psychiatr Res*. 2021;30(2):e1855. doi: 10.1002/mpr.1855
 20. Rostami R, Kazemi R, Khodaie-Ardakani MR, et al. The Persian version of the Calgary depression scale for schizophrenia (CDSS-P). *Asian J Psychiatry*. 2019;45:44–49. doi: 10.1016/j.ajp.2019.08.017
 21. Hettige NC, Bani-Fatemi A, Sakinofsky I, et al. A biopsychosocial evaluation of the risk for suicide in schizophrenia. *CNS Spectr*. 2018;23(4):253–263. doi: 10.1017/S1092852917000128
 22. Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. *Medicina (Kaunas)*. 2019;55(7):361. doi: 10.3390/medicina55070361
 23. Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. *JAMA Psychiatry*. 2018;75(3):254–260. doi: 10.1001/jamapsychiatry.2017.4437
 24. Schwarz E, Guest P, Rahmoune H et al. Identification of a biological signature for schizophrenia in serum. *Mol Psychiatry* 17. (2012);494–502. doi: 10.1038/mp.2011.42
 25. Stoeber G, Opler LA, Reis HJ, Schmitt A, Convit A, Lawrie SM, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. *World J Biol Psychiatry*. 2009;10(2):127–55. doi: 10.1080/15622970802573031
 26. DiCenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. *Evid Based Nurs*. 2009;12(4):99–101. doi: 10.1136/ebn.12.4.99
 27. Faugere M, Micoulaud-Franchi JA, Faget-Agius C, et al. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. *J Affect Disord*. 2018;225:671–675. doi: 10.1016/j.jad.2017.08.071
 28. Fang X, Chen L, Wang D, et al. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia. *Psychiatry Res*. 2019;281:112522. doi: 10.1016/j.psychres.2019.112522
 29. Xu J, Jiao Y, Xing M, et al. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. *Gen Psychiatr*. 2018;31(3):e100018. doi: 10.1136/gpsych-2018-100018
 30. Kumar P, Kraal AZ, Prawdzik AM, et al. Dietary glutamic acid, obesity, and depressive symptoms in patients with schizophrenia. *Front Psychiatry*. 2021;11:620097. doi: 10.3389/fpsy.2020.620097
 31. Miller BJ, McEvoy JP, McCall WV, et al. Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia. *Schizophr Res*. 2022;250:134–136. doi: 10.1016/j.schres.2022.11.01
 32. Lang XE, Zhang H, Wang N, et al. Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms. *Schizophr Res*. 2020;222:291–296. doi: 10.1016/j.schres.2020.05.032
 33. Bigseth TT, Engh JA, Egeland J, et al. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms. *BMC Psychiatry*. 2021;21(1):527. doi: 10.1186/s12888-021-03522-6
 34. Peng S, Li W, Lv L, et al. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. *Discov Med*. 2018;26(143):127–136.
 35. Manchia M, Isayeva U, Collu R, et al. Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. *Brain Sci*. 2022;12(12):1666. doi: 10.3390/brainsci12121666
 36. Wu Y, Du X, Yang R, et al. Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients with First-Episode and Drug-Naïve Schizophrenia. *Front Psychiatry*. 2022;13:911384. doi: 10.3389/fpsy.2022.911384
 37. Han D, Sun D, Xiu M, et al. Association between the improvement in depressive symptoms and serum BDNF levels in drug-naïve first episode patients with schizophrenia: a longitudinal follow-up. *Psychoneuroendocrinology*. 2021; 133:105392. doi: 10.1016/j.psyneuen.2021.105392
 38. Arabska J, Łucka A, Strzelecki D, et al. In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. *Neurosci Lett*. 2018;684:152–155. doi: 10.1016/j.neulet.2018.08.005
 39. van Erp TGM, Walton E, Hibar DP, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. *Biol Psychiatry*. 2018;84(9):644–654. doi: 10.1016/j.biopsych.2018.04.023
 40. Gray JP, Müller VI, Eickhoff SB, et al. Multimodal abnormalities of brain structure and function in major depressive disorder: a meta-analysis of neuroimaging studies. *Am J Psychiatry*. 2020;177(5):422–434. doi: 10.1176/appi.ajp.2019.19050560
 41. Siddi S, Nuñez C, Senior C, et al. Depression, auditory-verbal hallucinations, and delusions in patients with schizophrenia: Different patterns of association with prefrontal gray and white matter volume. *Psychiatry Res Neuroimaging*. 2019;283:55–63. doi: 10.1016/j.pscychresns.2018.12.001
 42. Wei GX, Ge L, Chen LZ, et al. Structural abnormalities of cingulate cortex in patients with first-episode drug-naïve schizophrenia comorbid with depressive symptoms. *Hum Brain Mapp*. 2021;42(6):1617–1625. doi: 10.1002/hbm.25315
 43. Zhuo C, Fang T, Chen C, et al. Brain imaging features in schizophrenia with co-occurring auditory verbal hallucinations and depressive symptoms – Implication for novel therapeutic strategies to alleviate the reciprocal deterioration. *Brain Behav*. 2021;11(2):e01991. doi: 10.1002/brb3.1991
 44. Ji F, Chen C, Chen M, et al. Brain impairment in chronic schizophrenia patients with depressive symptoms differs from brain impairment in chronic depression patients with psychotic symptoms. *Chin Med J (Engl)*. 2018;131(5):620–621. doi: 10.4103/0366-6999.226060
 45. Shor O, Yaniv-Rosenfeld A, Valevski A, et al. EEG-based spatio-temporal relation signatures for the diagnosis of depression and schizophrenia. *Sci Rep*. 2023;13(1):776. doi: 10.1038/s41598-023-28009-0
 46. Liu J, Zheng L, Fang T, et al. Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder — An evidence from

- mouse model. *Brain Behav.* 2021;11(5):e02113. doi: 10.1002/brb3.2113
47. Zhou C, Kong D, Zhu X, et al. Rethinking schizophrenia and depression comorbidity as one psychiatric disorder entity: evidence from mouse model. *Front Neurosci.* 2020;14:115. doi: 10.3389/fnins.2020.00115
48. Wan L, Li Y, Zhang Z, et al. Methylenetetrahydrofolate reductase and psychiatric diseases. *Transl Psychiatry.* 2018;8(1):242. doi: 10.1038/s41398-018-0276-6
49. Zhang Y, Zhao J, Wang W, et al. Homocysteine, but not MTHFR gene polymorphism, influences depressive symptoms in patients with schizophrenia. *J Affect Disord.* 2020;272:24–27. doi: 10.1016/j.jad.2020.03.121
50. Fang X, Chen Y, Wang Y, et al. Depressive symptoms in schizophrenia patients: a possible relationship between SIRT1 and BDNF. *Prog Neuropsychopharmacol Biol Psychiatry.* 2019;95:109673. doi: 10.1016/j.pnpbp.2019.109673
51. Shkundin A, Halaris A. Associations of BDNF/BDNF-AS SNPs with depression, schizophrenia, and bipolar disorder. *J Pers Med.* 2023;13(9):1395. doi: 10.3390/jpm13091395
52. Lu G, Li J, Zhang H, et al. Role and possible mechanisms of Sirt1 in depression. *Oxid Med Cell Longev.* 2018;2018:8596903. doi: 10.1155/2018/8596903
53. Wang D, Tang W, Zhao J, et al. A comprehensive analysis of the effect of SIRT1 variation on the risk of schizophrenia and depressive symptoms. *Front Genet.* 2020;11:832. doi: 10.3389/fgene.2020.00832
54. Broniarczyk-Czarnecki M, Szemraj J, Śmigielski J, et al. The role of OXT, OXTR, AVP, and AVPR1a gene expression in the course of schizophrenia. *Curr Issues Mol Biol.* 2022;44(1):336–349. doi: 10.3390/cimb44010025
55. Hughes ZH, Hughes LM, Khan SS. Genetic contributions to risk of adverse pregnancy outcomes. *Curr Cardiovasc Risk Rep.* 2023;17(11):185–193. doi: 10.1007/s12170-023-00729-y
56. Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. *Schizophr Res Cogn.* 2020;23:100193. doi: 10.1016/j.scog.2020.100193
57. Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: A systematic review. *Acta Psychiatr Scand.* 2018;137(5):380–390. doi: 10.1111/acps.12873
58. Lalouis PA, Schmaal L, Wood SJ, et al. Neurobiologically based stratification of recent-onset depression and psychosis: identification of two distinct transdiagnostic phenotypes. *Biol Psychiatry.* 2022;92(7):552–562. doi: 10.1016/j.biopsych.2022.03.021
59. Ruderfer DM, Ripke S, McQuillin A, et al. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. *Cell.* 2018;173(7):1705–1715.e16. doi: 10.1016/j.cell.2018.05.046
60. van Rooijen G, Vermeulen JM, Ruhé HG, et al. Treating depressive episodes or symptoms in patients with schizophrenia. *CNS Spectr.* 2019;24(2):239–248. doi: 10.1017/S1092852917000554
61. Naguy A. Depression in schizophrenia – A good or bad omen? *Asia Pac Psychiatry.* 2018;10(2):e12312. doi: 10.1111/appy.12312
62. Mosolov SN, Tsukarzi EE. Psychopharmacotherapy of schizophrenia. In: *Psihiatriya: nacional'noe rukovodstvo.* Moscow: GEOTAR-Media; 2021. p. 252–278. Russian.
63. Maslenikov NE, Tsukarzi EE, Mosolov SN. [Algorithm of biological treatment for depression in schizophrenia]. *Sovremennaja terapija psihicheskikh rasstrojstv.* 2019;(1):31–40. Russian. doi: 10.21265/PSYPH.2019.34.92.005
64. Edwards CJ, Garety P, Hardy A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. *Psychol Med.* 2019;49(15):2486–2498. doi: 10.1017/S0033291719002381
65. Guessoum SB, Le Strat Y, Dubertret C, et al. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. *Prog Neuropsychopharmacol Biol Psychiatry.* 2020;99:109862. doi: 10.1016/j.pnpbp.2020.109862
66. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatr Dis Treat.* 2020;16:519–534. doi: 10.2147/NDT.S225643
67. Demyttenaere K, Anthonis E, Correll CU. Depressive symptoms and PANSS symptom dimensions in patients with predominant negative symptom schizophrenia: a network analysis. *Front Psychiatry.* 2022;13:795866. doi: 10.3389/fpsy.2022.795866